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KEYWORDS	
	 Five	simple,	sensitive	and	precise	 spectrophotometric	and	chemometric	methods	were	used
for	 simultaneous	 determination	 of	 Simvastatin	 (SM)	 and	 Sitagliptin	 (SIT)	 in	 their	 pure
powdered	forms	and	in	the	tablets.	The	proposed	methods	are	the	extended	ratio	subtraction
method	 (EXRSM),	 ratio	 difference	method	 (RDSM),	mean	 centering	 of	 ratio	 spectra	method
(MCR)	and	chemometric	methods,	namely	principal	component	regression	(PCR)	and	partial
least	squares	(PLS).	In	EXRSM;	SM	was	determined	at	237.5	nm,	while	SIT	was	determined	at
267	nm,	 in	RDSM;	the	difference	 in	amplitudes	at	237.5	and	245.5	nm	was	used	 for	SM	and
263.5	and	248.0	nm	for	SIT,	while	 in	MCR;	SM	and	SIT	were	determined	at	239.0	and	273.0
nm,	respectively.	PCR	and	PLS	are	factor	based	multivariate	methods	which	utilize	the	whole
spectra	 of	 SM	 and	 SIT.	 The	 developed	 methods	 were	 successfully	 applied	 for	 the
determination	of	the	studied	drugs	in	their	bulk	powder,	laboratory	prepared	mixtures	and	in
tablets.	All	validation	parameters	of	 the	developed	methods	were	determined.	The	obtained
results	were	statistically	compared	with	each	other	along	with	a	reported	method.	
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1.	Introduction	
	
Simvastatin	 (SM)	 is	 a	 lipid‐lowering	 agent	 that	 is	 derived	
synthetically	 from	 the	 fermentation	 products	 of	 Aspergillus	
terreus.	After	oral	 ingestion	Simvastatin,	an	inactive	 lactone,	 is	
hydrolyzed	to	the	corresponding	ortho‐hydroxy	acid	leading	to	
the	 inhibition	 of	 3‐hydroxy	 3‐methyl	 glutaryl‐coenzyme	 A	
(HMG‐Co	A)	 reductase	which	 is	 responsible	 for	 catalysing	 the	
conversion	of	HMG‐Co	A	 to	mevalonate,	which	 is	an	early	and	
rate	 limiting	step	 in	cholesterol	biosynthesis	 [1,2].	 SM	(Figure	
1)	 is	chemically	designated	as	butanoic	acid,	2,2‐dimethyl‐,1,2,	
3,7,8,8a‐hexahydro‐3,7‐dimethyl‐8‐[2(tetrahydro‐4‐hydroxy‐6‐
oxo‐2H‐pyran‐2‐yl)‐ethyl]‐1‐naphthalenylester	(C25H38O5).	
	
	
	
Figure	1.	Chemical	structure	of	Simvastatin.
	
Sitagliptin	 (SIT)	 is	 an	 oral	 dipeptidyl	 peptidase‐4	 (DPP‐4)	
inhibitor,	which	improves	glycaemic	control	by	inhibiting	DPP‐
4	inactivation	of	the	incretin	hormones	glucagon‐like	peptide‐1	
(GLP‐1)	 and	 glucose‐dependent	 insulinotropic	 polypeptide	
(GIP).	 This	 increases	 active	 incretin	 and	 insulin	 levels	 and	
decreases	 glucagon	 levels	 and	 post‐glucose‐load	 glucose	
excursion	[3,4].	SIT	(Figure	2)	is	chemically	designated	as	(R)‐
4‐oxo‐4‐[3‐(trifluoromethyl)‐5,dihydro[1,2,4]triazolo[4,3‐a]	
pyrazin‐7(8H)‐yl]‐1‐(2,4,5‐trifluorophenyl)butan‐2‐amine	
(C16H15F6N5O).	
	
	
Figure	2.	Chemical	structure	of	Sitagliptin.	
	
Recently,	 the	 FDA	has	 approved	 a	 fixed‐dose	 combination	
tablet	 consisting	 of	 simvastatin	 and	 sitagliptin.	 It	 is	 the	 first	
registered	product	 in	which	a	drug	 treating	 type	2	diabetes	 is	
present	in	combination	with	cholesterol	lowering	drug.		
Many	 techniques	 like	UV‐Vis	 spectrophotometry	 [5,6]	 and	
HPLC	 [7‐12]	 have	 been	 reported	 for	 the	 determination	 of	 SM	
alone,	 in	 presence	 of	 its	 metabolites	 or	 in	 combination	 with	
other	 drugs.	 On	 the	 other	 hand,	 SIT	 was	 determined	 either	
alone	or	 in	presence	of	other	drugs	using	different	 techniques	
like	 UV‐Vis	 spectrophotometry	 [13],	 HPLC	 [14‐16],	 and	
fluorescence	spectroscopy	[17].	
In	 the	 last	 few	months,	a	 few	methods	were	published	 for	
the	simultaneous	determination	of	both	drugs.	These	methods	
include	 the	 use	 of	 spectrophotometric	 methods	 [18,19]	 and	
chromatographic	methods	[20,21].	
The	 aim	 of	 this	 work	 was	 to	 develop	 smart	 and	 simple	
methods	for	simultaneous	determination	of	SM	and	SIT	and	to	
conduct	 a	 comparative	 study	 between	 univariate	 and	
multivariate	methods	in	resolving	spectrally	overlapped	bands.	
The	univariate	methods	include	two	novel	spectrophotometric	
Lotfy	et	al.	/	European	Journal	of	Chemistry	4	(4)	(2013)	414‐421	 415	
 
methods;	namely	extended	ratio	subtraction	(EXRSM)	and	ratio	
difference	 (RDSM)	 and	 a	 well‐established	 mean	 centering	 of	
ratio	 spectra	 (MCR).	 While,	 multivariate	 calibration	 methods	
include	principal	component	regression	(PCR)	and	partial	least	
squares	(PLS).		
	
2.	Theory	
	
2.1.	Extended	ratio	subtraction	method	(EXRSM)	
	
Ratio	 subtraction	 method	 [22]	 is	 a	 well‐established	
method.	It	depends	on	that,	if	you	have	a	mixture	of	two	drugs	
Z	 and	 Y	 having	 overlapped	 spectra,	 you	 can	 determine	 Z	 by	
dividing	the	spectrum	of	the	mixture	by	a	known	concentration	
of	 Y	 as	 a	 divisor	 (Y').	 The	 division	will	 give	 a	 new	 curve	 that	
represents	
Z
+constant
Y'
.	 If	 we	 subtract	 this	 constant,	 then	
multiply	 the	 new	 curve	 obtained	 after	 subtraction	 by	 Y'	 (the	
divisor),	 therefore	 we	 can	 obtain	 the	 zero	 order	 curve	 (D0)	
curve	of	Z	again.	This	can	be	summarized	as	follows:	
	
Z+Y Z Y Z
= + = + constant
Y' Y' Y' Y'
	 	 	 (1)	
	
Z Z
+ constant ‐ constant =
Y' Y'
	 	 	 (2)	
	
Z
Y' = Z
Y'
 	 	 	 	 	 (3)	
	
For	 obtaining	 the	 second	 component	 (Y),	 an	 extension	 of	
the	 already	 developed	method	has	been	 established	 as	 a	 new	
approach	 in	 which	 Y	 could	 be	 determined	 by	 dividing	 the	
obtained	D0	spectrum	of	Z	by	a	known	concentration	of	Z	as	a	
divisor	(Z')	to	get	the	constant	
Z
Z'
.	By	dividing	the	spectrum	of	
the	mixture	 by	 the	 same	 divisor	 (Z').	 The	 division	will	 give	 a	
new	curve	that	represents	
Z+Y
Z'
	i.e	
Z Y
+
Z' Z'
	where	
Z
Z '
	is	the	
previously	obtained	constant.	If	we	subtract	this	constant,	then	
multiply	 the	 obtained	 curve	 by	 Z'	 (the	 divisor),	 therefore	 we	
can	obtain	a	new	curve	of	Y	representing	its	D0	curve.	
	
Y Z Z Y
+ ‐ = Z'=Y
Z' Z' Z' Z'
 	 	 	 	 (4)	
	
The	 concentration	 of	 Y	 was	 calculated	 from	 the	
corresponding	 regression	 equation	 (obtained	 by	 plotting	 the	
absorbance	 values	 of	 the	 zero	 order	 curves	 of	 Y	 at	 its	 max	
against	the	corresponding	concentrations).		
	
2.2.	Ratio	difference	spectrophotometric	method	(RDSM)	
[23]	
	
A	new	method	was	also	developed	in	which	the	amplitude	
difference	between	two	points	on	the	ratio	spectra	of	a	mixture	
is	directly	proportional	to	the	concentration	of	the	component	
of	 interest;	 independence	 of	 the	 interfering	 component	 is	 the	
basic	principle	of	the	ratio	difference	method.		
This	method	depends	on	that,	if	you	have	a	mixture	of	two	
drugs	Z	and	Y	having	overlapped	spectra,	you	can	determine	Z	
by	 dividing	 the	 spectrum	 of	 the	 mixture	 by	 a	 known	
concentration	of	Y	as	a	divisor	(Y').	The	division	will	give	a	new	
curve	 that	 represents	
Z+Y
Y'
	 i.e.	
Z Y
+
Y' Y'
,	 Where	
Y
Y'
	 is	 a	
constant.	 On	 the	 obtained	 ratio	 curve;	 by	 selecting	 2	
wavelengths	λ1	and	λ2	and	subtract	the	amplitude	at	these	two	
points,	the	constant	
Y
Y'
	will	be	cancelled	along	with	any	other	
instrumental	error	or	any	interference	from	the	sample	matrix.	
This	can	be	summarized	as	follows:	
	
Z+Y Z Y Z
= + = + constant
Y' Y' Y' Y'
	 	 	 (5)	
	
Suppose	the	amplitudes	at	the	two	selected	wavelength	are	
P1	and	P2	at	1	and	2,	respectively,	then;		
	
Z Z
P1‐P2=( )1 + constant‐{( )2+ constant}
Y' Y'
	 (6)	
	
Z Z
P1‐P2=( )1 ‐( )2
Y' Y'
	 	 	 	 (7)	
	
where;	P1	is	the	Peak	amplitudes	of	the	ratio	spectrum	at	1,	P2	
is	 the	 Peak	 amplitudes	 of	 the	 ratio	 spectrum	 at	 2.	 By	 using	
difference	between	P1	and	P2	the	interfering	substance	(Y)	will	
be	cancelled.	
The	 only	 requirement	 for	 the	 two	 chosen	 wavelengths	 is	
that	 both	 components	 should	 have	 a	 spectral	 contribution	 at	
those	wavelengths.	
The	 concentration	 of	 Z	 is	 calculated	 using	 the	 regression	
equation	 representing	 the	 linear	 correlation	 between	 the	
differences	 of	 ratio	 spectra	 amplitudes	 at	 the	 two	 selected	
wavelengths	to	the	corresponding	concentrations	of	drug	(Z).	
Similarly,	Y	could	be	determined	by	the	same	procedure	using	a	
known	concentration	of	Z	as	a	divisor.	
	
2.3.	Mean	centering	of	ratio	spectra	method	(MCR)	
	
This	 is	 a	 well‐established	 spectrophotometric	 method	 in	
which	both	binary	 and	 ternary	mixtures	 could	be	determined	
without	 previous	 separation.	 In	 this	method	 the	 ratio	 spectra	
are	 obtained	 after	 which	 the	 constant	 is	 removed	 by	 mean	
centering	process	[24‐26]		
	
3.	Experimental	
	
3.1.	Apparatus	
	
Spectrophotometer:	 SHIMADZU	 UV‐	 1601	 PC,	 dual	 beam	
UV‐Vis	spectrophotometer	with	two	matched	1	cm	quartz	cells,	
connected	to	an	IBM	compatible	personal	computer	and	a	HP‐
800	 inkjet	 printer.	 Bundled	 UV‐PC	 personal	 spectroscopy	
software	 version	 3.7	was	 used	 to	 process	 the	 absorption	 and	
the	 derivative	 spectra.	 The	 spectral	 band	 width	 was	 0.2	 nm	
with	wavelength	scanning	speed	of	2800	nm/min.	
	
3.2.	Software	
	
All	computations	were	performed	in	Matlab	for	Windows™	
version	 6.5	 [27].	 The	 PLS	 procedure	 was	 taken	 from	 PLS‐
Toolbox	[28]	for	use	with	Matlab®6.5.	
	
3.3.	Chemicals	and	reagents		
	
Pure	 samples:	 Pure	 simvastatin	 (SM)	 and	 sitagliptin	
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phosphate	monohydrate	 (SIT)	were	kindly	 supplied	by	Merck	
Sharp	 &	 Dohme	 International,	 USA.	 Distilled	 water	 from	
"Aquatron"	Automotive	water	Still	A	4000	(bibby	Sterillin	Ltd.,	
Staffordshire‐UK).	Methanol	(E.	Merck,	Darmstadt‐Germany).	
Market	samples:	Juvisync®	tablets,	labeled	to	contain	20	mg	
simvastatin	 and	 128.5	mg	 sitagliptin	 phosphate	monohydrate	
equivalent	 to	 100	 mg	 sitagliptin	 base	 per	 tablet	 (Batch	 No.	
G011008),	 manufactured	 by	 Merck	 Sharp	 &	 Dohme	
International,	USA	and	were	obtained	from	local	market.	
	
3.4.	Standard	solutions	
	
Standard	 solutions	 of	 Simvastatin	 (SM)	 (0.1	 mg/mL)	 and	
Sitagliptin	 phosphate	 monohydrate	 (SIT)	 (1	 mg/mL)	 were	
prepared	 separately	 by	 dissolving	 10	 mg	 and	 100	 mg,	
respectively,	 of	 the	pure	powder	 in	 30	mL	 of	methanol:water	
(1:1,	 v:v)	 solvent	 mixture	 into	 100	 mL	 volumetric	 flask	 with	
continuous	 shaking	 for	 about	 10	 minutes.	 The	 volume	 was	
completed	to	the	mark	with	the	corresponding	solvent.		
	
3.5.	Procedures	
	
3.5.1.	Spectral	characteristic	of	SM	and	SIT	
	
The	zero‐order	(D0)	absorption	spectra	of	18,	36	µg/mL	SM	
and	 360	 µg/mL	 of	 SIT	 were	 recorded	 against	 methanol	 as	 a	
blank	over	the	range	of	200‐300	nm.	
	
3.5.2.	Construction	of	calibration	curves	
	
Aliquots	equivalent	to	20.0‐180.0	µg	of	SM	and	0.2‐3.6	mg	
of	 SIT	 were	 accurately	 transferred	 from	 their	 respective	
standard	solutions	into	two	separate	sets	of	10	mL	volumetric	
flasks	then	completed	to	volume	with	methanol.	The	prepared	
solutions	 were	 scanned	 from	 200‐300	 nm	 and	 the	 scanned	
spectra	were	stored	in	the	computer.	
	
3.5.2.1.	Ratio	subtraction	coupled	with	extended	ratio	
subtraction	methods	(RS‐EXRSM)	
	
Standard	solutions	containing	2.0‐18.0	µg/mL	SM	and	20.0‐
120.0	 µg/mL	 SIT,	were	 prepared	 separately	 in	methanol.	 The	
absorption	 spectra	 of	 the	 resulting	 solution	 were	 measured.	
Construct	calibration	curve	relating	the	absorbance	of	the	zero	
order	 spectra	 of	 SM	 at	 237.5	nm	 and	 SIT	 at	 267.0	nm	vs.	 the	
corresponding	concentrations	of	SM	and	SIT,	respectively,	and	
the	regression	equations	were	computed.	
	
3.5.2.2.	Ratio	difference	method	(RDSM)	
	
Standard	solutions	containing	2.0‐18.0	µg/mL	SM	and	20.0‐
120.0	 µg/mL	 SIT,	were	 prepared	 separately	 in	methanol.	 The	
absorption	 spectra	 of	 the	 prepared	 solutions	 were	 recorded	
and	divided	by	the	absorption	spectra	of	360	µg/mL	SIT	and	18	
µg/mL	 SM,	 respectively.	 The	 calibration	 curves	 were	
constructed	 for	 SM	 and	 SIT	 by	 plotting	 the	 amplitudes	
difference	 between	 237.5	 and	 245.5	 nm	 for	 SM	 and	 between	
248.0and	 263.5	 nm	 for	 SIT	 versus	 the	 corresponding	
concentrations	and	the	regression	equations	were	computed.	
	
3.5.2.3.	Mean	centering	of	ratio	spectra	method	(MCR)	
	
The	 scanned	 spectra	 of	 2.0‐18.0	 µg/mL	 of	 SM	 and	 40.0‐
320.0	 µg/mL	 of	 SIT	 are	 exported	 to	 Matlab®	 for	 subsequent	
calculation.	The	spectra	of	SM	were	divided	by	the	normalized	
spectrum	of	SIT,	the	obtained	ratio	spectra	then	mean	centered.	
The	same	procedure	was	applied	to	SIT.	
The	 calibration	 curves	 for	 SM	 and	 SIT	 are	 constructed	 by	
plotting	 the	mean	 centered	values	 at	239	and	273	nm	 for	 the	
two	 drugs,	 respectively,	 versus	 the	 corresponding	 concent‐
ration	and	the	regression	equations	are	computed.	
3.5.3.	Determination	of	SM	and	SIT	in	laboratory	prepared	
mixtures	
	
Into	a	series	of	10	mL	volumetric	flasks	aliquots	of	SM	and	
SIT	 were	 accurately	 transferred	 from	 their	 corresponding	
standard	 solutions	 to	 prepare	 mixtures	 containing	 different	
ratios	of	the	two	drugs.	The	volumes	were	then	completed	with	
methanol.	The	spectra	of	the	prepared	solutions	were	recorded	
from	200‐300	nm	and	stored	in	the	computer.	The	procedures	
as	under	calibration	were	adopted,	and	then	the	concentration	
of	 each	 drug	 was	 calculated	 using	 the	 specified	 regression	
equation	
	
3.5.3.1.	Ratio	subtraction	coupled	with	extended	ratio	
subtraction	methods	(RS‐EXRSM)	
	
The	 spectra	 of	 the	 laboratory	 prepared	 mixtures	 were	
divided	 by	 the	 spectrum	of	 360.0	 µg/mL	of	 SIT,	 and	 then	 the	
absorbance	 in	 the	 plateau	 region	 at	 	 above	 275	 nm	 (the	
constants)	 was	 subtracted.	 The	 obtained	 curves	 were	 then	
multiplied	by	 the	 spectrum	of	360.0	µg/mL	standard	SIT	 (the	
divisor).	The	obtained	spectra	were	used	for	the	determination	
of	 SM	 constants	 at	 the	 plateau	 region	 230‐240	 nm	 were	
determined	after	dividing	it	using	18.0	µg/mL	standard	SM	as	a	
divisor.	 Then,	 the	 absorbance	 of	 the	 previously	 obtained	
constants	 was	 subtracted.	 The	 obtained	 curves	 were	 then	
multiplied	 by	 the	 spectrum	 of	 18.0	 µg/mL	 standard	 SM	 (the	
divisor).	 The	 obtained	 curves	 were	 then	 used	 for	 the	
determination	 of	 SIT	 at	 267	 nm	 using	 the	 corresponding	
regression	equation.	
	
3.5.3.2.	Ratio	difference	spectrophotometric	method	(RDSM)	
	
The	 absorption	 spectra	 of	 different	 laboratory	 prepared	
mixtures	 were	 divided	 by	 the	 absorption	 spectra	 of	 360.0	
µg/mL	 SIT	 and	 18.0	 µg/mL	 standard	 SM.	 The	 ratio	 spectra	
were	then	recorded	at	237.5	and	245.5	nm,	248.0	nm	and	263.5	
nm,	 for	 SM	 and	 SIT,	 respectively.	 The	 concentrations	 of	 the	
drugs	were	calculated	from	the	computed	regression	equations.	
	
3.5.3.3.	Mean	centering	of	ratio	spectra	(MCR)	
	
The	procedure	as	under	calibration	was	adopted,	and	then	
the	 concentration	 of	 each	 drug	 was	 calculated	 using	 the	
specified	regression	equation.	
	
3.5.3.4.	Chemometric	methods	
	
Experimental	 design	was	 used	 for	 the	 construction	 of	 the	
calibration	 and	 validation	 sets	 [29].	 A	 five‐level,	 two‐factor	
calibration	design	was	used	in	which	1.0‐5.0	mL	and	0.6‐1.4	mL	
aliquots	 of	 SM	 and	 SIT	 standard	 solutions,	 respectively,	were	
accurately	 transferred,	 combined	 and	 diluted	 to	 10	 mL	 with	
methanol.	 The	 absorption	 spectra	 of	 the	 prepared	 mixtures	
were	 recorded	 over	 the	 wavelength	 range	 200‐300	 nm	 and	
transferred	to	Matlab®	for	subsequent	calculations.	
	
3.5.4.	Application	of	the	proposed	methods	to	the	analysis	of	
SM	and	SIT	in	pharmaceutical	formulations	
	
Ten	 tablets	 (Juvisyc®	 tablets)	 were	 accurately	 weighed,	
crushed,	mixed	well	and	finely	powdered.	A	weight	equivalent	
to	10	mg	SIM	 and	64.25	mg	SIT	phosphate	monohydrate	was	
transferred	into	a	250	mL	beaker;	30	mL	70%	methanol	were	
added	 and	 stirred	 for~30	minutes	 then	 filtered	 into	 100	mL	
measuring	flask.	The	residue	was	washed	with	~2x20	mL	70%	
methanol,	 and	 then	 the	 volume	 was	 completed	 to	 the	 mark	
with	the	same	solvent	and	mixed	well.	One	mL	of	the	resulted	
solution	 was	 transferred	 to	 10	 mL	 measuring	 flask	 then	 the	
volume	was	completed	to	the	mark	using	the	same	solvent	and	
mixed	well.	The	general	procedure	was	followed	as	mentioned	
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before	and	 the	concentration	of	drug	was	 calculated	 from	 the	
corresponding	regression	equation.	
	
4.	Results	and	discussion		
	
The	 main	 task	 of	 this	 work	 was	 to	 establish	 simple,	
sensitive	and	accurate	analytical	methods	for	the	simultaneous	
determination	 of	 SM	 and	 SIT	 in	 their	 bulk	 powders	 and	
pharmaceutical	 dosage	 form	 with	 satisfactory	 precision	 for	
good	analytical	practice	(GAP).	As	well,	to	construct	a	statistical	
comparison	 between	 the	 ability	 of	 the	 proposed	 methods	 in	
determining	the	two	drugs.		
The	 overlapped	 absorption	 spectra	 of	 SM	 and	 SIT	 (Figure	
3)	 hinder	 their	 determination	 by	 direct	 spectrophotometry	
especially	in	the	presence	of	high	concentration	of	SM	as	in	the	
available	pharmaceutical	preparation.	
The	 choice	 of	 the	 divisors	 is	 a	 critical	 step,	 the	 selected	
divisors	 should	 compromise	 between	 minimal	 noise	 and	
maximum	sensitivity.	 Standard	 spectra	 of	 360	μg/mL	SIT	 and	
18	μg/mL	SM	were	the	best	tested	divisors	which	gave	the	best	
results	 regarding	 average	 recovery	 percent	 and	 standard	
deviation	for	the	determination	of	SM	and	SIT,	respectively.	
	
	
	
Figure	3.	The	 zero	order	 absorption	 spectra	of	 18,	 36	μg/mL	SM	 (___)	 and	
360	μg/mL	SIT	(‐	‐	‐)	in	methanol.	
	
4.1.	Univariate	calibration	
	
4.1.1.	Extended	ratio	subtraction	method	(EXRSM)		
	
The	 ratio	 subtraction	 method	 was	 applied	 to	 solve	 the	
mixture	 of	 SM	 (Z)	 and	 SIT	 (Y)	 of	 overlapping	 spectra	 by	
dividing	the	spectrum	of	the	mixture	by	a	standard	spectrum	of	
360	µg/mL	 SIT	 (Y')	 as	 a	 divisor.	 The	 division	will	 give	 a	 new	
curve	that	represents	
Z
+	constant
Y'
,	Figure	4.		
	
	
Figure	 4.	 Division	 spectra	 of	 laboratory	 prepared	 mixture	 of	 Simvastatin	
(SM)	10,	12,1	6	µg/mL	and	Sitagliptin	(SIT)	100,	60,	40	µg/mL	,	respectively	
using	360	µg/ml	of	SIT	as	a	divisor.	
If	we	subtract	this	constants	in	plateau	above	275	nm,	then	
multiply	 the	 new	 curve	 obtained	 after	 subtraction	 by	 Y'	 (the	
divisor),	 therefore	 we	 can	 obtain	 the	 original	 zero	 order	
spectrum	 of	 SM	 (Z)	 in	 the	 mixture,	 Figure	 5.	 The	 obtained	
curves	were	used	 for	direct	determination	of	 SM	at	237.5	nm	
and	calculation	of	the	concentration	SM	in	the	mixture	from	the	
corresponding	 regression	 equation	 (obtained	 by	 plotting	 the	
absorbance	values	of	the	zero	order	curves	of	SIT	at	237.5	nm	
against	the	corresponding	concentrations).	
	
	
Figure	5.	Zero	order	absorption	spectra	Simvastatin	(SM)	10,	12,	16	µg/mL	
after	subtraction	of	the	constants	and	multiplication	by	the	spectrum	of	360	
µg/mL	of	SIT.
	
The	determination	of	SIT	(Y)	could	be	done	by	the	extended	
ratio	subtraction	by	dividing	these	obtained	spectrum	of	SM	by	
carefully	 chosen	 standard	 spectrum	 of	 SM	 (18	 µg/mL)	
producing	 ratio	 spectrum	 represent	 the	 constant	 SM/SM	 in	
plateau	 (230‐240	nm),	 Figure	 6.	 The	 previously	 scanned	 zero	
order	absorption	spectrum	of	the	laboratory‐prepared	mixture	
(SM	 and	 SIT),	 dividing	 by	 the	 standard	 SM	 (Z')	 as	 a	 divisor	
producing	 a	 new	 ratio	 spectrum	 that	 represent	 SIT/SM	 +	
constant,	 then	by	subtraction	of	 the	obtained	constant	SM/SM	
followed	 by	 multiplication	 of	 the	 obtained	 spectrum	 by	 the	
standard	SM	(Z')	(the	divisor).	Finally,	the	original	spectrum	of	
(SIT)	 Y	 could	 be	 obtained	 which	 are	 used	 for	 direct	
determination	of	SIT	at	267	nm,	Figure	7	and	calculation	of	the	
concentration	 SIT	 in	 the	 mixture	 from	 the	 corresponding	
regression	 equation	 (obtained	 by	 plotting	 the	 absorbance	
values	 of	 the	 zero	 order	 curves	 of	 SIT	 at	 267	 nm	 against	 the	
corresponding	concentrations).	
	
	
Figure	 6. Division	 spectra	 of	 laboratory	 prepared	 mixture	 of	 Simvastatin	
(SM)	10,	12,	16	µg/mL	and	Sitagliptin	(SIT)	100,	60,	40	µg/mL	,	respectively	
using	18	µg/mL	of	SM	as	a	divisor.	
	
The	 EXRSM	 has	 the	 advantage	 that	 the	 two	 drugs	 in	 the	
mixture	 could	 be	 determined	 at	 their	 max	 in	 contrary	 to	 the	
previously	established	ratio	subtraction	method	[22]	 in	which	
only	the	spectrally	un‐extended	drug	could	be	determined.	This	
method	is	valid	for	the	analysis	of	binary	and	ternary	mixtures	
with	extended	spectra.		
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Figure	 7.	 Zero	 order	 absorption	 spectrum	 of	 Sitagliptin	 (SIT)	 40,	 60,	 100	
µg/mL	after	subtraction	of	the	constants	and	multiplication	by	the	spectrum	
of	18	µg/mL	of	SM.	
	
4.1.2.	Ratio	difference	spectrophotometric	method	(RDSM)	
	
The	absorption	spectra	of	SM	(Z)	and	SIT	(Y)	show	severe	
overlapping	that	prevents	the	use	of	direct	spectrophotometry	
for	 the	 analysis	 of	 either	 SIT	 or	 SM	 without	 preliminary	
separation,	Figure	3.	The	absorption	spectrum	of	the	mixture	is	
scanned	 and	 divided	 by	 the	 standard	 absorption	 spectrum	 of	
one	of	its	components,	and	the	ratio	spectrum	is	then	obtained	
which	represents	
	
SM
+constant
SIT'
	or	
SIT
+constant
SM'
			 	 (9)	
	
This	 was	 applied	 to	 solve	 the	 problem	 of	 the	 overlapped	
absorption	spectra	of	the	cited	drugs	using	the	difference	in	the	
amplitudes	of	the	ratio	spectra		
	
SM SM
( )1‐( )2
SIT' SIT'
	or	 )
SIT' SIT'
( )1‐( 2
SM SM
	 	 (10)	
	
where,	 the	 interfering	 substance	 was	 cancelled	 and	
subsequently	shows	no	interference.	The	method	was	suitable	
for	 the	 simultaneous	 determination	 of	 SM	 and	 SIT.	 The	
interfering	 substance	 must	 have	 spectral	 contribution	 at	 the	
two	 selected	wavelengths	 and	 the	 ratio	 value	 at	 the	 selected	
wavelengths	 should	 be	with	 significant	 value	 to	minimize	 the	
error.	
The	 amplitudes	 at	 237.5	 and	 245.5	 nm	were	 selected	 for	
determination	 of	 SM	 (Z)	 using	 ratio	 spectrum	 of	 the	 mixture	
and	SIT	(360	µg/mL)	as	a	divisor,	Figure	8.	Similarly,	 the	 two	
selected	wavelengths	for	the	estimation	of	SIT	(Y)	using	SM	(18	
µg/mL)	as	a	divisor	were	248	nm	and	263.5	nm,	Figure	9.		
	
	
Figure	8.	The	ratio	spectra	of	10	μg/mL	SM	(____),	360	μg/mL	SIT	(_	_	_	)	and	
a	mixture	containing	10	μg/mL	SM	and	360	μg/mL	SIT	(___	)	using	a	divisor	
of	360	μg/mL	SIT	in	methanol.	
	
	
Figure	9. The	ratio	spectra	of	60	μg/mL	SIT	(____),	18	μg/mL	SM	(____)	and	a	
mixture	containing	60	μg/mL	SIT	and	18	μg/mL	SM	(____)	using	a	divisor	of	
18	μg/mL	SM	in	methanol.	
	
4.1.3.	Mean	centering	of	the	ratio	spectra	method	(MCR)	
	
As	shown	in	Figure	3,	the	absorption	spectra	of	SM	and	SIT	
show	 spectral	 overlap.	 So,	 the	 absorption	 spectra	 of	 the	
standard	 solutions	 of	 the	 SM	 with	 different	 concentrations	
were	 recorded	 in	 the	 wavelength	 range	 of	 200‐300	 nm	 and	
divided	 by	 the	 normalized	 spectrum	 of	 SIT	 and	 the	 obtained	
ratio	 spectra	 were	 mean	 centered	 (Figure	 10).	 The	
concentration	 of	 SM	 was	 determined	 by	 measuring	 the	
amplitude	at	239	nm	corresponding	to	maxima.	
	
	
	
Figure	10. Mean	centered	ratio	spectra	of	2‐18	μg	/mL	SM	using	normalized	
SIT	as	a	divisor.	
	
The	 absorption	 spectra	 of	 the	 standard	 solutions	 of	 SIT	
were	 recorded	 in	 the	 wavelength	 range	 of	 200‐300	 nm	 and	
divided	 by	 the	 normalized	 spectrum	 of	 SM	 and	 the	 obtained	
ratio	 spectra	 were	 then	 mean	 centered	 (Figure	 11).	 The	
concentration	 of	 SIT	 was	 determined	 by	 measuring	 the	
amplitude	 at	 273	 nm	 corresponding	 to	maxima.	 The	 effect	 of	
divisor	 concentration	 on	 the	 analytical	 parameters	 such	 as	
slope,	 intercept	 and	 correlation	 coefficient	 of	 the	 calibration	
graphs	was	also	tested.	Different	concentrations	of	divisor	were	
used	but	 it	was	observed	 that	changing	the	concentration	had	
no	 significant	 effect	 in	 their	 linear	 calibration	 range	 and	 the	
calculated	 analytical	 parameters.	 Therefore,	 a	 normalized	
spectrum	of	each	of	SM	and	SIT	was	used	as	divisor	spectrum	in	
the	proposed	method.	
	
4.2.	Multivariate	calibration	methods	
	
Multivariate	calibration	methods	are	very	useful	in	spectral	
analysis	 as	 the	 simultaneous	 inclusion	 of	 many	 spectral	
wavelengths	 instead	 of	 using	 a	 single	 wavelength	 greatly	
improves	the	precision	and	predictive	ability	of	these	methods	
[30].		
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Table	1.	Validation	and	regression	parameters	of	determination	of	Simvastatin	(SM)	and	Sitagliptin	(SIT)	by	the	proposed	methods	*.	
Parameter	 EXRSM	 RDSM	 MCR Chemometric	methods	
PCR	 PLS	
SM	 SIT	 SM	 SIT	 SM	 SIT	 SM	 SIT	 SM	 SIT	
Range	(µg/mL)	 2‐18	 40‐240	 2‐18	 20‐120	 2‐18	 40‐320	 8	‐16	 40‐120	 8	‐16	 40	‐120	
Slope	 0.0601	 0.0035	 0.3599	 0.0369	 13.088	 9.1388	 0.9833	 0.9759	 0.9833	 0.9756	
SE	of	slope	 0.1321	 2.9954	 0.0326	 0.07363 0.00087 0.00093 0.0174 0.0201	 0.01741	 0.0198
Intercept	 0.0059	 0.0030	 0.0846	 0.0093 6.8961 48.861 0.075 0.8454	 0.0752	 0.8453
SE	of	intercept	 0.0901	 1.4753	 0.1343	 0.2123 0.1297 1.1751 0.2169 1.8021	 0.2167	 1.777
R	 0.9998	 0.9997	 0.9995	 0.9999 0.9993 0.9997 0.9991 0.9996	 0.9990	 0.9994
Accuracy	 100.03	
±0.222	
100.13	
±0.135	
99.98	
±0.468	
100.07	
±0.743	
99.67	
±	0.525	
99.34	
±0.874	
99.99	
±0.435	
101.11	
±0.682	
99.97	
±0.654	
101.10	
±0.678	
Precision	 0.564	 0.432	 0.687	 0.598	 0.984	 0.785	 0.763	 0.853	 0.541	 0.874	
LOD	 0.0765	 0.432	 0.0987	 0.498	 0.0398	 0.7419	 0.4377	 4.245	 0.437	 4.19	
LOQ	 0.232	 1.309	 0.299	 1.509 0.1207 2.2469 1.3265 12.863	 1.326	 12.697
RMSEP	 ‐	 ‐	 ‐	 ‐ ‐ ‐ 0.18342 1.8021	 0.18335	 1.8188
*	EXRSM:	Extended	ratio	subtraction	method,	RDSM:	Ratio	difference	spectrophotometric	method,	MCR:	Mean	centering	ratio	spectrophotometric	method,	PCR:	
Principal	component	regression,	PLS:	Partial	least	squares.	
	
	
Table	2.	Determination	of	simvastatin	(SM)	and	sitagliptin	(SIT)	in	laboratory	prepared	mixtures	and	tablets	by	the	proposed	methods	and	the	results	obtained	
by	applying	standard	addition	technique	*.	
Sample	 EXRSM	 RDSM	 MCR	 Chemometric	methods	
SM	 SIT SM SIT SM SIT PCR PLS	
SM SIT	 SM	 SIT
Lab.	mixture	 99.98	
±0.325	
99.99	
±0.215	
100.01	
±0.216	
99.97	
±0.633	
100.34	
±0.654	
99.98	
±0.987	
101.67	
±0.934	
99.34	
±0.657	
101.66	
±0.560	
99.29	
±0.654	
Juvisync	tablet	
labeled	to	contain	20	mg	SM	and	128.5	mg	SIT	
phosphate	 equivalent	 to	 100	 mg	 sitagliptin	
base/tablet	(B.N.	G011008)	
100.26	
±0.493	
100.28	
±0.404	
99.90	
±0.087	
100.48	
±0.299	
99.65	
	±	.277	
99.49	
±0.263	
99.90	
±0.089	
101.17	
±0.364	
99.91	
±0.328	
101.04	
±0.280	
Standard	addition	 100.05	
±0.376	
99.27
±0.588	
100.34
±0.717	
100.03
±0.647	
98.34
±0.798	
98.99
±0.923	
100.23	
±0.343	
98.99	
±0.608	
100.21
±0.344	
99.01
±0.723	
*	EXRSM:	Extended	ratio	subtraction	method,	RDSM:	Ratio	difference	spectrophotometric	method,	MCR:	Mean	centering	ratio	spectrophotometric	method,	PCR:	
Principal	component	regression,	PLS:	Partial	least	squares,	B.N.:	Batch	number.	
	
	
	
	
Figure	11.	Mean	centered	ratio	spectra	of	40‐320	μg	/mL	SIT	using	normalized	SM	as	a	divisor.	
	
	
For	spectral	resolution	of	SM	and	SIT,	two	different	regression	
models	were	constructed	and	used	for	the	determination	of	SM	
and	SIT	in	their	pure	forms,	laboratory	prepared	mixtures	and	
in	pharmaceutical	preparation.	These	multivariate	methods	are	
PCR	and	PLS.	
	
4.2.1.	Experimental	design	of	the	calibration	and	validation	
sets		
	
Brereton	 [29]	 constructed	multilevel‐multifactor	design	 in	
which,	 the	 levels	 (L)	 are	 the	 concentrations	 used	 and	 the	
number	of	experiments	is	L2.	For	the	calibration	and	validation	
sets,	 different	 laboratory	 prepared	 mixtures	 of	 SM	 and	 SIT	
were	prepared.	The	concentration	range	for	SM	and	SIT	are	8‐
16	 and	 40‐120	 µg/mL,	 respectively.	 The	 spectra	 of	 the	
prepared	mixtures	were	recorded	in	the	range	of	200‐300	nm	
and	 the	 spectral	 data	 acquisition	 was	 taken	 with	 0.1	 nm	
intervals,	 thus	 producing	 501	 data	 points	 per	 spectrum,	 thus	
the	 produced	 spectral	 data	 matrix	 has	 25	 rows	 representing	
different	 samples	 and	 501	 columns	 representing	wavelengths	
(25×501).	 Seventeen	 samples	 were	 chosen	 and	 used	 for	
calibration	and	eight	were	used	for	external	validation	
	
4.2.2.	PCR	and	PLS	models	
	
In	order	to	apply	PCR	and	PLS	to	the	data,	the	raw	data	of	
the	 calibration	 samples	 were	 mean	 centered	 [31]	 as	 a	
preprocessing	 step	 and	 random	 subsets	 was	 applied	 as	 an	
internal	cross	validation	method	[32].	To	choose	the	optimum	
number	 of	 significant	 latent	 variables,	 F	 statistics	 [33]	 was	
applied.		
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Table	3.	 Statistical	analysis	of	 the	proposed	methods	and	 the	 reported	 spectroscopic	methods	 [6,12]	 for	 simvastatin	 (SM)	and	 sitagliptin	 (SIT)	 in	 their	pure	
powdered	forms	and	their	dosage	form	*.	
Parameter	 EXRSM	 RDSM	 MCR	 Chemometric	methods	
PCR PLS	
SM	 SIT SM	 SIT SM SIT SM SIT SM	 SIT
Pure	powders	 	 	 	 	
Mean	 100.09	 100.22	 100.46	 99.98 100.33 99.69 98.97 98.68	 98.97	 98.64
Variance	 2.411	 1.750	 2.062	 0.399	 1.386	 2.183	 1.010	 2.145	 1.011	 2.063	
n	 8	 8	 8	 8	 8	 8	 8	 8	 8	 8	
t‐test	 0.7878	
(2.228)	
0.744	
(2.2009)	
0.735	
(2.2009)	
0.901
(2.228)	
0.131
(2.2009)	
0.5506
(2.2009)	
2.080
(2.2009)	
2.1409	
(2.2009)	
2.078	
(2.2009)	
2.189
(2.2009)	
F‐test	 4.6127	
(4.876)	
3.109	
(4.876)	
3.944	
(4.876)	
1.409
(5.050)	
2.653
(4.876)	
3.879
(4.876)	
1.933
(4.876)	
3.813	
(4.876)	
1.932	
(4.876)	
3.666
(4.876)	
Dosage	form	
Mean	 100.26	 100.28	 99.90	 100.48 99.65 99.49 99.90 101.17	 99.71	 101.04
Variance	 0.243	 0.163	 0.007	 0.089 0.077 0.069 0.008 0.132	 0.108	 0.078
n	 5	 5	 5	 5	 5	 5	 5	 5	 5	 5	
t‐test	(2.571)	 2.122	 1.472	 1.481	 2.191 0.677 0.876 1.495 2.139	 0.278	 1.945
F‐test	(6.388)	 5.926	 2.703	 5.434	 4.932 1.871 6.362 5.148 3.334	 2.625	 5.625
*	EXRSM:	Extended	ratio	subtraction	method,	RDSM:	Ratio	difference	spectrophotometric	method,	MCR:	Mean	centering	ratio	spectrophotometric	method,	PCR:	
Principal	component	regression,	PLS:	Partial	least	squares,	n:	Number	of	experiments.	
	
Table	4.	One	way	ANOVA	testing	for	the	proposed	methods	used	for	the	determination	of	simvastatin	(SM)	and	sitagliptin	(SIT).	
Source	of	variation	 SS	 df MS F p‐value	 F‐crit
SM	 	 	
Between	Groups	 18.24850152	 5 3.6497003 2.008816 0.097609	 2.443429
Within	Groups	 74.49051575	 41 1.8168418 	
Total	 92.73901727	 46 		
SIT	 		 		
Between	Groups	 18.96108818	 5 3.7922176 2.331831 0.060948	 2.462548
Within	Groups	 61.79875336	 38 1.626283 	
Total	 80.75984155	 43 		
*	SS:	Sum	of	squares,	df:	Degree	of	freedom,	MS:	Means	of	squares,	F:	Calculated	F	value,	F‐crit:	Tabulated	F	value,	p‐value:	Probability.	
	
	
After	 the	 PCR	 and	 PLS	 models	 have	 been	 constructed,	 it	
was	 found	 that	 the	 optimum	number	of	 LVs	described	by	 the	
developed	models	was	two	factors	for	PCR	and	PLS.	
Calibration	 graphs	 were	 constructed	 by	 plotting	 the	
predicted	 concentrations	 for	 each	 compound	 by	 each	 of	 the	
developed	 models	 versus	 the	 true	 concentrations.	 The	
statistical	 parameters	 of	 the	 linear	 relationship	 between	 the	
calculated	 and	 the	 true	 concentration	 of	 SM	 and	 SIT	 in	 the	
calibration	set	are	represented	in	Table	1.		
In	 order	 to	 assess	 the	 predictive	 ability	 of	 each	 of	 the	
developed	models,	it	was	applied	on	an	external	validation	set	
for	determination	of	the	two	components.	The	recoveries,	mean	
recoveries,	standard	deviation,	relative	standard	deviation	and	
RMSEP	values	are	 summarized	 in	Table	2.	 It	 is	 clear	 from	 the	
obtained	results	 that	the	two	models	are	of	equal	efficacy	and	
described	 by	 three	 factors;	 both	 models	 were	 successfully	
applied	for	the	determination	of	SM	and	SIT	in	pharmaceutical	
dosage	form.	
The	 proposed	 univariate	 and	 multivariate	 methods	 were	
successfully	 applied	 for	 the	 determination	 of	 SM	 and	 SIT	 in	
laboratory	 prepared	 mixtures	 and	 in	 tablets	 with	 good	
recovery	 as	 shown	 in	 Table	 3.	 The	 results	 obtained	 by	 those	
methods	 statistically	 compared	 by	 each	 other	 and	 by	 those	
obtained	 upon	 applying	 the	 reported	 methods	 [6,12]	 and	 no	
significant	 difference	 has	 been	 observed	 regarding	 to	 both	
accuracy	and	precision,	Table	4.		
	
4.3.	Method	validation	
	
Validation	 was	 done	 according	 to	 ICH	 recommendations	
[34].	
	
4.3.1.	Linearity	
	
The	linearity	of	the	methods	was	evaluated	by	analyzing	6	
concentrations	of	SM	and	 concentrations	of	SIT	between	2‐18	
µg/mL	and	20‐360	µg/mL	respectively.	Each	concentration	was	
repeated	 three	 times.	 The	 assay	 was	 performed	 according	 to	
the	 experimental	 conditions	previously	mentioned.	The	 linear	
equations	were	summarized	in	Table	1.	
	
4.3.2.	Accuracy	
	
The	 accuracy	 of	 the	 results	 was	 checked	 by	 applying	 the	
proposed	methods	for	determination	of	different	blind	samples	
of	 SM	 and	 SIT.	 The	 concentrations	 were	 obtained	 from	 the	
corresponding	 regression	 equations.	 From	 which	 the	
percentage	 recoveries	 suggested	 good	 accuracy	 of	 the	
proposed	 methods	 were	 calculated	 with	 mean	 percentage	
recovery	shown	in	(Table	1).		
	
4.3.3.	Range	
	
The	 calibration	 range	 was	 established	 through	
considerations	 of	 the	 practical	 range	 necessary	 according	 to	
adherence	 to	Beer’s	 law	and	 the	 concentration	of	 SM	and	 SIT	
present	 in	 the	 pharmaceutical	 preparations	 to	 give	 accurate	
precise	and	linear	results	(Table	1).	
	
4.3.4.	Selectivity	
	
Selectivity	of	 the	methods	was	achieved	by	the	analysis	of	
different	 laboratory	 prepared	mixtures	 of	 SM	 and	 SIT	within	
the	linearity	range.	Satisfactory	results	were	shown	in	Table	3.	
	
4.3.5.	Precision	
	
4.3.5.1.	Repeatability	
	
Three	concentrations	of	SM	(6,	12,	18	µg/mL)	and	SIT	(40,	
60,	120	µg/mL)	were	analyzed	three	times	intra‐daily	using	the	
proposed	 methods.	 The	 relative	 standard	 deviations	 were	
calculated	(Table	1).	
	
4.3.5.2.	Intermediate	precision	
	
The	 previous	 procedures	 were	 repeated	 inter‐daily	 on	
three	 different	 days	 for	 the	 analysis	 of	 the	 three	 chosen	
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concentrations.	 The	 relative	 standard	 deviations	 were	
calculated	(Table	1).	
	
4.3.6.	Application	of	the	method	in	assay	of	tablets	
	
The	 proposed	 UV	 methods	 were	 applied	 for	 the	
determination	of	SM	and	SIT	in	their	combined	pharmaceutical	
formulation	and	 the	 results	 are	 shown	 in	 (Table	2).	 The	good	
recoveries	confirm	the	suitability	of	the	proposed	methods	for	
the	 routine	 determination	 of	 these	 components	 in	 combined	
formulation.	
	
4.3.7.	Statistical	Analysis	
	
Results	 obtained	 by	 the	 proposed	 procedures	 for	 the	
determination	 of	 SM	 and	 SIT	 in	 pure	 form	 and	 in	
pharmaceutical	dosage	form	are	statistically	compared	to	those	
obtained	by	 the	 reported	methods	 [6,12].	 The	 results	 showed	
no	significant	differences	between	them	(Table	4).	
	
5.	Conclusion	
	
It	 could	 be	 concluded	 that	 the	 proposed	 procedures	 are	
simple,	do	not	require	sophisticated	techniques	or	instruments.	
They	 are	 also	 sensitive	 and	 selective	 and	 could	 be	 used	 for	
routine	 analysis	 of	 SM	 and	 SIT	 in	 their	 available	 dosage	 form	
without	 prior	 separation.	 The	 methods	 are	 also	 suitable	 and	
valid	 for	 application	 in	 laboratories	 lacking	 liquid	
chromatographic	instruments.	
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